APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Nuclear Medicine Software

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nuclear Medicine Software Market Outlook and Growth Opportunities 2026

Report ID 174198950422 January 2026199 pages

Choose your research edition.

Industry ResearchNuclear Medicine Software Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Nuclear Medicine Software Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Nuclear Medicine Software Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nuclear Medicine Software Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Nuclear Medicine Software Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Nuclear Medicine Software market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nuclear Medicine Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nuclear Medicine Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nuclear Medicine Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nuclear Medicine Software market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nuclear Medicine Software market include iQ IMAGE, Mediso, Segami, Hermes Medical Solutions, MIM Software Inc, LabLogic, scintido, Gamma Gurus and Mirion Medical, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Nuclear Medicine Software market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nuclear Medicine Software and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nuclear Medicine Software revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Nuclear Medicine Software market.

Nuclear Medicine Software Segment by Company

iQ IMAGE

Mediso

Segami

Hermes Medical Solutions

MIM Software Inc

LabLogic

scintido

Gamma Gurus

Mirion Medical

PAIRE

GE HealthCare

Inter Medical

Sirona

Nuclear Medicine Software Segment by Type

Drug Management

Radiation Management

Other

Nuclear Medicine Software Segment by Application

Clinical Diagnosis

Research

Others

Nuclear Medicine Software Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Nuclear Medicine Software status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Nuclear Medicine Software key companies, revenue, market share, and recent developments.

3. To split the Nuclear Medicine Software breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Nuclear Medicine Software market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nuclear Medicine Software significant trends, drivers, influence factors in global and regions.

6. To analyze Nuclear Medicine Software competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Medicine Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nuclear Medicine Software and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Medicine Software.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nuclear Medicine Software industry.

Chapter 3: Detailed analysis of Nuclear Medicine Software company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Nuclear Medicine Software in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Nuclear Medicine Software in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nuclear Medicine Software Industry Trends Table 2. Nuclear Medicine Software Industry Drivers Table 3. Nuclear Medicine Software Industry Opportunities and Challenges Table 4. Nuclear Medicine Software Industry Restraints Table 5. Global Nuclear Medicine Software Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nuclear Medicine Software Revenue Share by Company (2021-2026) Table 7. Global Nuclear Medicine Software Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Nuclear Medicine Software Key Company Manufacturing Base & Headquarters Table 9. Global Nuclear Medicine Software Company, Product Type & Application Table 10. Global Nuclear Medicine Software Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Nuclear Medicine Software by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Drug Management Table 15. Significant Companies of Radiation Management Table 16. Significant Companies of Other Table 17. Global Nuclear Medicine Software Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Nuclear Medicine Software Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Nuclear Medicine Software Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Nuclear Medicine Software Sales Value Share by Type (2021-2026) Table 21. Global Nuclear Medicine Software Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Clinical Diagnosis Table 23. Significant Companies of Research Table 24. Significant Companies of Others Table 25. Global Nuclear Medicine Software Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Nuclear Medicine Software Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Nuclear Medicine Software Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Nuclear Medicine Software Sales Value Share by Application (2021-2026) Table 29. Global Nuclear Medicine Software Sales Value Share by Application (2027-2032) Table 30. Global Nuclear Medicine Software Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Nuclear Medicine Software Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Nuclear Medicine Software Sales Value Share by Region (2021-2026) Table 33. Global Nuclear Medicine Software Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Nuclear Medicine Software Sales Value Share by Region (2027-2032) Table 35. Global Nuclear Medicine Software Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Nuclear Medicine Software Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Nuclear Medicine Software Sales Value Market Share by Country (2021-2026) Table 38. Global Nuclear Medicine Software Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Nuclear Medicine Software Sales Value Market Share by Country (2027-2032) Table 40. iQ IMAGE Company Information Table 41. iQ IMAGE Business Overview Table 42. iQ IMAGE Nuclear Medicine Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. iQ IMAGE Nuclear Medicine Software Product Portfolio Table 44. iQ IMAGE Recent Development Table 45. Mediso Company Information Table 46. Mediso Business Overview Table 47. Mediso Nuclear Medicine Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Mediso Nuclear Medicine Software Product Portfolio Table 49. Mediso Recent Development Table 50. Segami Company Information Table 51. Segami Business Overview Table 52. Segami Nuclear Medicine Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Segami Nuclear Medicine Software Product Portfolio Table 54. Segami Recent Development Table 55. Hermes Medical Solutions Company Information Table 56. Hermes Medical Solutions Business Overview Table 57. Hermes Medical Solutions Nuclear Medicine Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Hermes Medical Solutions Nuclear Medicine Software Product Portfolio Table 59. Hermes Medical Solutions Recent Development Table 60. MIM Software Inc Company Information Table 61. MIM Software Inc Business Overview Table 62. MIM Software Inc Nuclear Medicine Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. MIM Software Inc Nuclear Medicine Software Product Portfolio Table 64. MIM Software Inc Recent Development Table 65. LabLogic Company Information Table 66. LabLogic Business Overview Table 67. LabLogic Nuclear Medicine Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. LabLogic Nuclear Medicine Software Product Portfolio Table 69. LabLogic Recent Development Table 70. scintido Company Information Table 71. scintido Business Overview Table 72. scintido Nuclear Medicine Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. scintido Nuclear Medicine Software Product Portfolio Table 74. scintido Recent Development Table 75. Gamma Gurus Company Information Table 76. Gamma Gurus Business Overview Table 77. Gamma Gurus Nuclear Medicine Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Gamma Gurus Nuclear Medicine Software Product Portfolio Table 79. Gamma Gurus Recent Development Table 80. Mirion Medical Company Information Table 81. Mirion Medical Business Overview Table 82. Mirion Medical Nuclear Medicine Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Mirion Medical Nuclear Medicine Software Product Portfolio Table 84. Mirion Medical Recent Development Table 85. PAIRE Company Information Table 86. PAIRE Business Overview Table 87. PAIRE Nuclear Medicine Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. PAIRE Nuclear Medicine Software Product Portfolio Table 89. PAIRE Recent Development Table 90. GE HealthCare Company Information Table 91. GE HealthCare Business Overview Table 92. GE HealthCare Nuclear Medicine Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. GE HealthCare Nuclear Medicine Software Product Portfolio Table 94. GE HealthCare Recent Development Table 95. Inter Medical Company Information Table 96. Inter Medical Business Overview Table 97. Inter Medical Nuclear Medicine Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Inter Medical Nuclear Medicine Software Product Portfolio Table 99. Inter Medical Recent Development Table 100. Sirona Company Information Table 101. Sirona Business Overview Table 102. Sirona Nuclear Medicine Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Sirona Nuclear Medicine Software Product Portfolio Table 104. Sirona Recent Development Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. Nuclear Medicine Software Product Image Figure 2. Global Nuclear Medicine Software Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nuclear Medicine Software Market Size (2021-2032) & (US$ Million) Figure 4. Global Nuclear Medicine Software Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Drug Management Image Figure 8. Radiation Management Image Figure 9. Other Image Figure 10. Global Nuclear Medicine Software Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Nuclear Medicine Software Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Nuclear Medicine Software Sales Value Share by Type (2021-2032) Figure 13. Clinical Diagnosis Image Figure 14. Research Image Figure 15. Others Image Figure 16. Global Nuclear Medicine Software Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Nuclear Medicine Software Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Nuclear Medicine Software Sales Value Share by Application (2021-2032) Figure 19. Global Nuclear Medicine Software Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Nuclear Medicine Software Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Nuclear Medicine Software Sales Value (2021-2032) & (US$ Million) Figure 22. North America Nuclear Medicine Software Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Nuclear Medicine Software Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Nuclear Medicine Software Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Nuclear Medicine Software Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Nuclear Medicine Software Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Nuclear Medicine Software Sales Value (2021-2032) & (US$ Million) Figure 28. South America Nuclear Medicine Software Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Nuclear Medicine Software Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Nuclear Medicine Software Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Nuclear Medicine Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Drug Management
  • Radiation Management
  • Other
Applications
  • Clinical Diagnosis
  • Research
  • Others
Companies covered
  • iQ IMAGE
  • Mediso
  • Segami
  • Hermes Medical Solutions
  • MIM Software Inc
  • LabLogic
  • scintido
  • Gamma Gurus
  • Mirion Medical
  • PAIRE
  • GE HealthCare
  • Inter Medical
  • Sirona

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nuclear Medicine Software Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nuclear Medicine Software Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Nuclear Medicine Software Market Dynamics
  1. 2.1 Nuclear Medicine Software Industry Trends
  2. 2.2 Nuclear Medicine Software Industry Drivers
  3. 2.3 Nuclear Medicine Software Industry Opportunities and Challenges
  4. 2.4 Nuclear Medicine Software Industry Restraints
3 Nuclear Medicine Software Market by Company
  1. 3.1 Global Nuclear Medicine Software Company Revenue Ranking in 2025
  2. 3.2 Global Nuclear Medicine Software Revenue by Company (2021-2026)
  3. 3.3 Global Nuclear Medicine Software Company Ranking (2024-2026)
  4. 3.4 Global Nuclear Medicine Software Company Manufacturing Base and Headquarters
  5. 3.5 Global Nuclear Medicine Software Company Product Type and Application
  6. 3.6 Global Nuclear Medicine Software Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Nuclear Medicine Software Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Nuclear Medicine Software Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Nuclear Medicine Software Market by Type
  1. 4.1 Nuclear Medicine Software Type Introduction
  2. 4.1.1 Drug Management
  3. 4.1.2 Radiation Management
  4. 4.1.3 Other
  5. 4.2 Global Nuclear Medicine Software Sales Value by Type
  6. 4.2.1 Global Nuclear Medicine Software Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Nuclear Medicine Software Sales Value by Type (2021-2032)
  8. 4.2.3 Global Nuclear Medicine Software Sales Value Share by Type (2021-2032)
5 Nuclear Medicine Software Market by Application
  1. 5.1 Nuclear Medicine Software Application Introduction
  2. 5.1.1 Clinical Diagnosis
  3. 5.1.2 Research
  4. 5.1.3 Others
  5. 5.2 Global Nuclear Medicine Software Sales Value by Application
  6. 5.2.1 Global Nuclear Medicine Software Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Nuclear Medicine Software Sales Value by Application (2021-2032)
  8. 5.2.3 Global Nuclear Medicine Software Sales Value Share by Application (2021-2032)
6 Nuclear Medicine Software Regional Value Analysis
  1. 6.1 Global Nuclear Medicine Software Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nuclear Medicine Software Sales Value by Region (2021-2032)
  3. 6.2.1 Global Nuclear Medicine Software Sales Value by Region: 2021-2026
  4. 6.2.2 Global Nuclear Medicine Software Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nuclear Medicine Software Sales Value (2021-2032)
  7. 6.3.2 North America Nuclear Medicine Software Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Nuclear Medicine Software Sales Value (2021-2032)
  10. 6.4.2 Europe Nuclear Medicine Software Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Nuclear Medicine Software Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Nuclear Medicine Software Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Nuclear Medicine Software Sales Value (2021-2032)
  16. 6.6.2 South America Nuclear Medicine Software Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Nuclear Medicine Software Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Nuclear Medicine Software Sales Value Share by Country, 2025 VS 2032
7 Nuclear Medicine Software Country-level Value Analysis
  1. 7.1 Global Nuclear Medicine Software Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nuclear Medicine Software Sales Value by Country (2021-2032)
  3. 7.2.1 Global Nuclear Medicine Software Sales Value by Country (2021-2026)
  4. 7.2.2 Global Nuclear Medicine Software Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Nuclear Medicine Software Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Nuclear Medicine Software Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Nuclear Medicine Software Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 iQ IMAGE
  2. 8.1.1 iQ IMAGE Company Information
  3. 8.1.2 iQ IMAGE Business Overview
  4. 8.1.3 iQ IMAGE Nuclear Medicine Software Revenue and Gross Margin (2021-2026)
  5. 8.1.4 iQ IMAGE Nuclear Medicine Software Product Portfolio
  6. 8.1.5 iQ IMAGE Recent Developments
  7. 8.2 Mediso
  8. 8.2.1 Mediso Company Information
  9. 8.2.2 Mediso Business Overview
  10. 8.2.3 Mediso Nuclear Medicine Software Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Mediso Nuclear Medicine Software Product Portfolio
  12. 8.2.5 Mediso Recent Developments
  13. 8.3 Segami
  14. 8.3.1 Segami Company Information
  15. 8.3.2 Segami Business Overview
  16. 8.3.3 Segami Nuclear Medicine Software Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Segami Nuclear Medicine Software Product Portfolio
  18. 8.3.5 Segami Recent Developments
  19. 8.4 Hermes Medical Solutions
  20. 8.4.1 Hermes Medical Solutions Company Information
  21. 8.4.2 Hermes Medical Solutions Business Overview
  22. 8.4.3 Hermes Medical Solutions Nuclear Medicine Software Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Hermes Medical Solutions Nuclear Medicine Software Product Portfolio
  24. 8.4.5 Hermes Medical Solutions Recent Developments
  25. 8.5 MIM Software Inc
  26. 8.5.1 MIM Software Inc Company Information
  27. 8.5.2 MIM Software Inc Business Overview
  28. 8.5.3 MIM Software Inc Nuclear Medicine Software Revenue and Gross Margin (2021-2026)
  29. 8.5.4 MIM Software Inc Nuclear Medicine Software Product Portfolio
  30. 8.5.5 MIM Software Inc Recent Developments
  31. 8.6 LabLogic
  32. 8.6.1 LabLogic Company Information
  33. 8.6.2 LabLogic Business Overview
  34. 8.6.3 LabLogic Nuclear Medicine Software Revenue and Gross Margin (2021-2026)
  35. 8.6.4 LabLogic Nuclear Medicine Software Product Portfolio
  36. 8.6.5 LabLogic Recent Developments
  37. 8.7 scintido
  38. 8.7.1 scintido Company Information
  39. 8.7.2 scintido Business Overview
  40. 8.7.3 scintido Nuclear Medicine Software Revenue and Gross Margin (2021-2026)
  41. 8.7.4 scintido Nuclear Medicine Software Product Portfolio
  42. 8.7.5 scintido Recent Developments
  43. 8.8 Gamma Gurus
  44. 8.8.1 Gamma Gurus Company Information
  45. 8.8.2 Gamma Gurus Business Overview
  46. 8.8.3 Gamma Gurus Nuclear Medicine Software Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Gamma Gurus Nuclear Medicine Software Product Portfolio
  48. 8.8.5 Gamma Gurus Recent Developments
  49. 8.9 Mirion Medical
  50. 8.9.1 Mirion Medical Company Information
  51. 8.9.2 Mirion Medical Business Overview
  52. 8.9.3 Mirion Medical Nuclear Medicine Software Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Mirion Medical Nuclear Medicine Software Product Portfolio
  54. 8.9.5 Mirion Medical Recent Developments
  55. 8.10 PAIRE
  56. 8.10.1 PAIRE Company Information
  57. 8.10.2 PAIRE Business Overview
  58. 8.10.3 PAIRE Nuclear Medicine Software Revenue and Gross Margin (2021-2026)
  59. 8.10.4 PAIRE Nuclear Medicine Software Product Portfolio
  60. 8.10.5 PAIRE Recent Developments
  61. 8.11 GE HealthCare
  62. 8.11.1 GE HealthCare Company Information
  63. 8.11.2 GE HealthCare Business Overview
  64. 8.11.3 GE HealthCare Nuclear Medicine Software Revenue and Gross Margin (2021-2026)
  65. 8.11.4 GE HealthCare Nuclear Medicine Software Product Portfolio
  66. 8.11.5 GE HealthCare Recent Developments
  67. 8.12 Inter Medical
  68. 8.12.1 Inter Medical Company Information
  69. 8.12.2 Inter Medical Business Overview
  70. 8.12.3 Inter Medical Nuclear Medicine Software Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Inter Medical Nuclear Medicine Software Product Portfolio
  72. 8.12.5 Inter Medical Recent Developments
  73. 8.13 Sirona
  74. 8.13.1 Sirona Company Information
  75. 8.13.2 Sirona Business Overview
  76. 8.13.3 Sirona Nuclear Medicine Software Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Sirona Nuclear Medicine Software Product Portfolio
  78. 8.13.5 Sirona Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst